At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 64 enrolled
Drug / intervention
Nadroparin calcium, warfarindrug
Likely dose
Nadroparin calcium, warfarin 0.75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients：A Randomized Controlled Trial
In Brief
A Phase 4 clinical trial evaluating Nadroparin calcium, warfarin for Liver Cirrhosis and Portal Vein Thrombosis. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Portal Vein Thrombosis
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedNov 2019
Primary CompletionJan 2020
TodayJul 2026
First PostedNov 22, 2019
Enrollment StartJan 1, 2017
Primary CompletionJan 31, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.6 years ago
Interventions
Nadroparin calcium, warfarindrug
Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.